StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Somil Mehta, Sharekhan

BUYGlenmark Pharmaceuticals
Glenmark Pharmaceuticals share price target & all analyst calls

bySomil Mehta, SharekhanHorizon: NA (inferred Swing (≤2wk))19 Oct 2026via Zee Business (Live)

Entry₹2,229.7Inferred
Target₹2,400
Total upside +7.64%
Stop loss₹2,120-4.92% risk
CMP₹2,210.2Just now
Active-0.87%+8.59%upside left 13d left
Follow Somil Mehta for new calls(22% target hit, 243 closed calls)Get alertsWatch GLENMARK for new buy/sell callsGet alertsSee 1 other Swing call on GLENMARKSee 77 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 20 Oct, 2:39 pm IST
7 supporting2 opposing
Supports the BUY call (7)

Glenmark Pharmaceuticals Launches GLIPIQ® (Semaglutide) in India with Weekly Treatment Starting at ₹325

NewsGoogle News·19 Oct · yesterday

(opens in new tab)

Glenmark Pharma's biotech arm IGI unveils ISB 2301 to target solid tumors

NewsGoogle News·17 Oct · 3d ago

(opens in new tab)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·13 Oct · 1w ago

Glenmark stock gained 0.70 percent after US acne launch

NewsGoogle News·7 Oct · 2w ago

(opens in new tab)

Glenmark Therapeutics Inc. USA has launched Pump Packs for Adapalene Gel USP, 0.1% (OTC), expanding its product portfolio in the US market.

BSE · Company Update·6 Oct · 2w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (2)

MACD below its signal line — bearish momentum

Technicals · macd·20 Oct · today

Glenmark USA settles antitrust suits for $29.628 million

NewsGoogle News·18 Oct · yesterday

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Somil Mehta, Sharekhan

Every call and its outcome